27 results on '"Sara J. Adair"'
Search Results
2. Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth
- Author
-
Sarbajeet Nagdas, Jennifer A. Kashatus, Aldo Nascimento, Syed S. Hussain, Riley E. Trainor, Sarah R. Pollock, Sara J. Adair, Alex D. Michaels, Hiromi Sesaki, Edward B. Stelow, Todd W. Bauer, and David F. Kashatus
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Summary: Mitochondria undergo fission and fusion to maintain homeostasis, and tumors exhibit the dysregulation of mitochondrial dynamics. We recently demonstrated that ectopic HRasG12V promotes mitochondrial fragmentation and tumor growth through Erk phosphorylation of the mitochondrial fission GTPase Dynamin-related protein 1 (Drp1). However, the role of Drp1 in the setting of endogenous oncogenic KRas remains unknown. Here, we show that Drp1 is required for KRas-driven anchorage-independent growth in fibroblasts and patient-derived pancreatic cancer cell lines, and it promotes glycolytic flux, in part through the regulation of hexokinase 2 (HK2). Furthermore, Drp1 deletion imparts a significant survival advantage in a model of KRas-driven pancreatic cancer, and tumors exhibit a strong selective pressure against complete Drp1 deletion. Rare tumors that arise in the absence of Drp1 have restored glycolysis but exhibit defective mitochondrial metabolism. This work demonstrates that Drp1 plays dual roles in KRas-driven tumor growth: supporting both glycolysis and mitochondrial function through independent mechanisms. : Nagdas et al. find that the mitochondrial fission GTPase Drp1 is required for KRas-driven transformation and pancreatic tumor growth. The inhibition of Drp1 in cells expressing oncogenic KRas leads to impaired glycolytic flux and the eventual loss of mitochondrial metabolic function. Keywords: Drp1, mitochondria, metabolism, KRas, pancreatic cancer
- Published
- 2019
- Full Text
- View/download PDF
3. Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates
- Author
-
Craig L Slingluff, Walter C Olson, Christine A Tran, Arabinda Mandal, Jagathpala Shetty, Mriganka Mandal, Bhupal Ban, Eusebio S Pires, Sara J Adair, Todd W Bauer, and John C Herr
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Sperm acrosomal SLLP1 binding (SAS1B) protein is found in oocytes, which is necessary for sperm-oocyte interaction, and also in uterine and pancreatic cancers. Anti-SAS1B antibody-drug conjugates (ADCs) arrested growth in these cancers. However, SAS1B expression in cancers and normal tissues has not been characterized. We hypothesized that SAS1B is expressed on the surface of other common solid cancer cells, but not on normal tissue cells, and might be selectively targeted therapeutically.Methods SAS1B expression in human normal and cancer tissues was determined by immunohistochemistry, and complementary DNA (cDNA) libraries were employed to PCR amplify human SAS1B and its transcripts. Monoclonal antibodies (mAbs) to human SAS1B were generated using mouse hybridomas. SAS1B deletion constructs were developed to map SAS1B’s epitope, enabling the creation of a blocking peptide. Indirect immunofluorescence (IIF) of human transfected normal and cancer cells was performed to assess SAS1B expression. SAS1B intracellular versus surface expression in normal and tumor tissues was evaluated by flow cytometry after staining with anti-SAS1B mAb, with specificity confirmed with the blocking peptide. Human cancer lines were treated with increasing mAb and ADC concentrations. ATP was quantitated as a measure of cell viability.Results SAS1B expression was identified in a subset of human cancers and the cytoplasm of pancreatic islet cells. Two new SAS1B splice variants were deduced. Monoclonal antibodies were generated to SAS1B splice variant A. The epitope for mAbs SB2 and SB5 is between SAS1B amino acids 32–39. IIF demonstrated intracellular SAS1B expression in transfected kidney cells and on the cell surface of squamous cell lung carcinoma. Flow cytometry demonstrated intracellular SAS1B expression in all tumors and some normal cells. However, surface expression of SAS1B was identified only on cancer cells. SB2 ADC mediated dose-dependent cytotoxic killing of multiple human cancer lines.Conclusion SAS1B is a novel cancer-oocyte antigen with cell surface expression restricted to cancer cells. In vitro, it is an effective target for antibody-mediated cancer cell lysis. These findings support further exploration of SAS1B as a potential therapeutic cancer target in multiple human cancers, either with ADC or as a chimeric antigen receptor-T (CAR-T) cell target.
- Published
- 2024
- Full Text
- View/download PDF
4. Data from Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
- Author
-
Todd W. Bauer, J. Thomas Parsons, Edward B. Stelow, Rosa F. Hwang, Amy H. Bouton, Keena S. Thomas, Bryce Lowrey, E. Dan Hershey, Robert W. Tilghman, Dustin M. Walters, Jill K. Slack-Davis, Sara J. Adair, and Jayme B. Stokes
- Abstract
Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells. Focal adhesion kinase (FAK) is activated in PDA, and levels are inversely associated with survival. We investigated the effects of PF-562,271 (a small-molecule inhibitor of FAK/PYK2) on (i) in vitro migration, invasion, and proliferation; (ii) tumor proliferation, invasion, and metastasis in a murine model; and (iii) stromal cell composition in the PDA microenvironment. Migration assays were conducted to assess tumor and stromal cell migration in response to cellular factors, collagen, and the effects of PF-562,271. An orthotopic murine model was used to assess the effects of PF-562,271 on tumor growth, invasion, and metastasis. Proliferation assays measured PF-562,271 effects on in vitro growth. Immunohistochemistry was used to examine the effects of FAK inhibition on the cellular composition of the tumor microenvironment. FAK and PYK2 were activated and expressed in patient-derived PDA tumors, stromal components, and human PDA cell lines. PF-562,271 blocked phosphorylation of FAK (phospho-FAK or Y397) in a dose-dependent manner. PF-562,271 inhibited migration of tumor cells, cancer-associated fibroblasts, and macrophages. Treatment of mice with PF-562,271 resulted in reduced tumor growth, invasion, and metastases. PF-562,271 had no effect on tumor necrosis, angiogenesis, or apoptosis, but it did decrease tumor cell proliferation and resulted in fewer tumor-associated macrophages and fibroblasts than control or gemcitabine. These data support a role for FAK in PDA and suggest that inhibitors of FAK may contribute to efficacious treatment of patients with PDA. Mol Cancer Ther; 10(11); 2135–45. ©2011 AACR.
- Published
- 2023
5. supplementary Figure Legends 1-2 from Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
- Author
-
Todd W. Bauer, J. Thomas Parsons, Edward B. Stelow, Rosa F. Hwang, Amy H. Bouton, Keena S. Thomas, Bryce Lowrey, E. Dan Hershey, Robert W. Tilghman, Dustin M. Walters, Jill K. Slack-Davis, Sara J. Adair, and Jayme B. Stokes
- Abstract
PDF file - 72K
- Published
- 2023
6. Supplementary Figure 1 from Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
- Author
-
Todd W. Bauer, J. Thomas Parsons, Edward B. Stelow, Rosa F. Hwang, Amy H. Bouton, Keena S. Thomas, Bryce Lowrey, E. Dan Hershey, Robert W. Tilghman, Dustin M. Walters, Jill K. Slack-Davis, Sara J. Adair, and Jayme B. Stokes
- Abstract
PDF file - 48K
- Published
- 2023
7. Supplementary Figure 2 from Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment
- Author
-
Todd W. Bauer, J. Thomas Parsons, Edward B. Stelow, Rosa F. Hwang, Amy H. Bouton, Keena S. Thomas, Bryce Lowrey, E. Dan Hershey, Robert W. Tilghman, Dustin M. Walters, Jill K. Slack-Davis, Sara J. Adair, and Jayme B. Stokes
- Abstract
PDF file - 85K
- Published
- 2023
8. Supplemental legend from CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
- Author
-
Todd W. Bauer, J. Thomas Parsons, Kodi S. Ravichandran, Craig L. Slingluff, Timothy N. J. Bullock, Jesse B. Persily, Matthew G. Mullen, Sarbajeet Nagdas, Bernadette J. Goudreau, Sho Morioka, Sara J. Adair, Timothy E. Newhook, and Alex D. Michaels
- Abstract
Supplemental legend
- Published
- 2023
9. Data from CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
- Author
-
Todd W. Bauer, J. Thomas Parsons, Kodi S. Ravichandran, Craig L. Slingluff, Timothy N. J. Bullock, Jesse B. Persily, Matthew G. Mullen, Sarbajeet Nagdas, Bernadette J. Goudreau, Sho Morioka, Sara J. Adair, Timothy E. Newhook, and Alex D. Michaels
- Abstract
Purpose: Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only 2 years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases to identify adjuvant treatment strategies that could prolong survival.Experimental Design: A murine splenic injection model of hepatic micrometastatic PDAC was used with five patient-derived PDAC tumors. The impact of liver macrophages on tumor growth was assessed by (i) depleting mouse macrophages in nude mice with liposomal clodronate injection, and (ii) injecting tumor cells into nude versus NOD-scid-gamma mice. Immunohistochemistry and flow cytometry were used to measure CD47 (“don't eat me signal”) expression on tumor cells and characterize macrophages in the tumor microenvironment. In vitro engulfment assays and mouse experiments were performed with CD47-blocking antibodies to assess macrophage engulfment of tumor cells, progression of micrometastases in the liver and mouse survival.Results: In vivo clodronate depletion experiments and NOD-scid-gamma mouse experiments demonstrated that liver macrophages suppress the progression of PDAC micrometastases. Five patient-derived PDAC cell lines expressed variable levels of CD47. In in vitro engulfment assays, CD47-blocking antibodies increased the efficiency of PDAC cell clearance by macrophages in a manner which correlated with CD47 receptor surface density. Treatment of mice with CD47-blocking antibodies resulted in increased time-to-progression of metastatic tumors and prolonged survival.Conclusions: These findings suggest that following surgical resection of PDAC, adjuvant immunotherapy with anti-CD47 antibody could lead to substantially improved outcomes for patients. Clin Cancer Res; 24(6); 1415–25. ©2017 AACR.
- Published
- 2023
10. Automated biophysical classification of apoptotic pancreatic cancer cell subpopulations by using machine learning approaches with impedance cytometry
- Author
-
Carlos Honrado, Armita Salahi, Sara J. Adair, John H. Moore, Todd W. Bauer, and Nathan S. Swami
- Subjects
Machine Learning ,Pancreatic Neoplasms ,Electric Impedance ,Tumor Microenvironment ,Biomedical Engineering ,Humans ,Apoptosis ,Bioengineering ,General Chemistry ,Flow Cytometry ,Biochemistry - Abstract
Unrestricted cell death can lead to an immunosuppressive tumor microenvironment, with dysregulated apoptotic signaling that causes resistance of pancreatic cancer cells to cytotoxic therapies. Hence, modulating cell death by distinguishing the progression of subpopulations under drug treatment from viable towards early apoptotic, late apoptotic, and necrotic states is of interest. While flow cytometry after fluorescent staining can monitor apoptosis with single-cell sensitivity, the background of non-viable cells within non-immortalized pancreatic tumors from xenografts can confound distinction of the intensity of each apoptotic state. Based on single-cell impedance cytometry of drug-treated pancreatic cancer cells that are obtained from tumor xenografts with differing levels of gemcitabine sensitivity, we identify the biophysical metrics that can distinguish and quantify cellular subpopulations at the early apoptotic
- Published
- 2022
11. A histone methylation-MAPK signaling axis drives durable epithelial-mesenchymal transition in hypoxic pancreas cancer
- Author
-
Brooke A. Brown, Paul J. Myers, Sara J. Adair, Jason R. Pitarresi, Shiv K. Sah-Teli, William S. Hart, Michelle Barbeau, Kelsey Leong, Nicholas Seyler, William Kane, Kyoung Eun Lee, Edward Stelow, M. Celeste Simon, Peppi Koivunen, Todd W. Bauer, Ben Z. Stanger, and Matthew J. Lazzara
- Abstract
Here, we show that hypoxia drives especially long-lasting epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC) primarily through a positive-feedback histone methylation-MAPK signaling axis. We find that neoplastic PDAC cells preferentially undergo EMT in hypoxic tumor regions in multiple model systems and that hypoxia drives a cell-autonomous EMT in PDAC cells which, unlike EMT in response to growth factors, can last for weeks. We further demonstrate that hypoxia reduces histone demethylase KDM2A activity, suppresses PP2 family phosphatase expression, and activates MAPKs to post-translationally stabilize histone methyltransferase NSD2, leading to an H3K36me2-dependent EMT in which hypoxia-inducible factors play only a supporting role. This mechanism can be antagonizedin vivoby combinations of MAPK inhibitors that may be effective in multi-drug therapies designed to target EMT.
- Published
- 2022
12. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells
- Author
-
Anindya Dutta, Mazhar Adli, Cem Kuscu, Denis Liu, Xiaolong Wei, Alaa Hamdi Habieb, Yusuf Mert Demirlenk, Sara J. Adair, Patrick Edward O'Hara, Todd W. Bauer, Jiekun Yang, Ebru Yilmaz, Kyung Yong Lee, and William J. Kane
- Subjects
Protein-Arginine N-Methyltransferases ,endocrine system diseases ,Cell Survival ,DNA damage ,DNA repair ,Druggability ,Mice, Nude ,Antineoplastic Agents ,Synthetic lethality ,Deoxycytidine ,Gene Knockout Techniques ,Drug Development ,In vivo ,Cell Line, Tumor ,Pancreatic cancer ,medicine ,Animals ,Humans ,CRISPR ,Replication protein A ,Multidisciplinary ,business.industry ,Protein arginine methyltransferase 5 ,Cancer ,Biological Sciences ,medicine.disease ,Xenograft Model Antitumor Assays ,Gemcitabine ,Pancreatic Neoplasms ,Cancer research ,CRISPR-Cas Systems ,business ,medicine.drug - Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancer to treat. Due to the asymptomatic nature of the disease and ineffective drug treatment modalities, the survival rate of PDAC patients remains one of the lowest. The recurrent genetic alterations in PDAC are yet to be targeted; therefore, identifying effective therapeutic combinations is desperately needed. Here, we performed anin vivoCRISPR screening in a clinically relevant patient-derived xenograft (PDX) model system to identify synergistic drug combinations for PDAC treatment. Our approach revealed protein arginine methyltransferase gene 5 (PRMT5) as a promising druggable candidate whose inhibition creates synergistic vulnerability of PDAC cells to gemcitabine. Genetic and pharmacological inhibition results indicate that of PRMT5 depletion results in synergistic cytotoxicity with Gem due to depleted replication protein A (RPA) levels and an impaired non-homology end joining (NHEJ) DNA repair. Thus, the novel combination creates conditional lethality through the accumulation of excessive DNA damage and cell death, bothin vitroandin vivo. The findings demonstrate that unbiased genetic screenings combined with a clinically relevant model system is an effective approach in identifying synthetic lethal drug combinations for cancer treatment.STATEMENT of SIGNIFICANCEIdentify synergistic drug combinations for PDAC is a significant unmet need. Through CRISPR screening, we discovered and validated that PRMT5 depletion creates synergistic vulnerability of PDAC cells to gemcitabine. Mechanistically, the combination impairs DNA repair, synergistic accumulation of DNA damage and cell deathin vitroandin vivo.
- Published
- 2020
13. Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry
- Author
-
Walter Varhue, John H. Moore, Edik M. Blais, Sarbajeet Nagdas, Sara J. Adair, John S. McGrath, Armita Salahi, Nathan S. Swami, Carlos Honrado, Todd W. Bauer, Bernadette J. Goudreau, and Vahid Farmehini
- Subjects
Cell type ,Microfluidics ,Cell ,02 engineering and technology ,Adenocarcinoma ,01 natural sciences ,Biochemistry ,Article ,Analytical Chemistry ,Proto-Oncogene Proteins p21(ras) ,Mice ,Cell Line, Tumor ,Electric Impedance ,medicine ,Animals ,Humans ,Environmental Chemistry ,Pancreas ,Gene ,Spectroscopy ,Genetic heterogeneity ,Chemistry ,010401 analytical chemistry ,021001 nanoscience & nanotechnology ,Phenotype ,0104 chemical sciences ,Electrophysiology ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Liver ,Cytoplasm ,Cancer research ,Heterografts ,Single-Cell Analysis ,0210 nano-technology ,Cytometry ,Carcinoma, Pancreatic Ductal - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer lacking specific biomarkers that can be correlated to disease onset, promotion and progression. To assess whether tumor cell electrophysiology may serve as a marker for PDAC tumorigenicity, we use multi-frequency impedance cytometry at high throughput (∼350 cells/s) to measure the electrical phenotype of single PDAC tumor cells from xenografts, which are derived from primary pancreatic tumors versus those from liver metastases of different patients. A novel phase contrast metric based on variations in the high and low frequency impedance phase responses that is related to electrophysiology of the cell interior is found to be systematically altered as a function of tumorigenicity. PDAC cells of higher tumorigenicity exhibited lowered interior conductivity and enhanced permittivity, which is validated by the dielectrophoresis on the respective cell types. Using genetic analysis, we suggest the role of dysregulated Na+ transport and removal of Ca2+ ions from the cytoplasm on key oncogenic KRAS-driven processes that may be responsible for lowering of the interior cell conductivity. We envision that impedance cytometry can serve as a tool to quantify phenotypic heterogeneity for rapidly stratifying tumorigenicity. It can also aid in protocols for dielectrophoretic isolation of cells with a particular phenotype for prognostic studies on patient survival and to tailor therapy selection to specific patients.
- Published
- 2020
14. Abstract C054: Hypoxia promotes a durable epithelial-mesenchymal transition in pancreas cancer through a histone methylation-MAPK signaling axis
- Author
-
Brooke A. Brown, Paul J. Myers, Sara J. Adair, Jason R. Pitarresi, Shiv Sah Teli, Peppi Karppinen, Ben Z. Stanger, Todd W. Bauer, and Matthew J. Lazzara
- Subjects
Cancer Research ,Oncology - Abstract
Pancreatic ductal adenocarcinoma (PDAC) tumors are poorly vascularized and exhibit regions of hypoxia. Here, we demonstrate that this feature of the tumor microenvironment promotes epithelial-mesenchymal transition (EMT), which occurs early in PDAC and drives chemoresistance, and we identify the underlying signaling mechanism. Analysis of publicly-available human transcriptomics and proteomics demonstrated that PDAC cells or tumors enriched in mesenchymal markers were also enriched in markers of hypoxia or HIF activity. Furthermore, in lineage-traced autochthonous, orthotopic patient-derived xenograft, and orthotopic or subcutaneous implanted cell line models of PDAC, hypoxic tumor tissue regions were enriched for neoplastic cells that had undergone EMT. In cell culture experiments, PDAC cells from human and mouse tumors exhibited an ability to undergo EMT in response to 1% O2, with loss of membranous E-cadherin, increased vimentin protein expression, and transcriptional changes indicative of both hypoxia and EMT. Moreover, EMT in response to hypoxia was substantially more persistent than that observed in response to growth factors, and a hypoxia fate mapping system revealed that once-hypoxic cells could retain mesenchymal characteristics outside hypoxic tumor regions. To understand the mechanism for EMT in response to low oxygen tension, we constructed a multivariable linear regression model of the dependence of the hypoxic gene signature on different gene sets in PDAC ductal cells, which identified MAPK signaling as the most important feature. Consistent with the model inference, in both in vitro and in vivo settings, hypoxic cells showing evidence of EMT displayed elevated MAPK signaling. We further demonstrated that MAPK activation in hypoxia was potentiated by suppressed activity of a histone demethylase and concomitant loss of protein phosphatase expression, which reinforced the mechanism by stabilizing the expression of a histone methyltransferase. Thus, this study identifies a tumor microenvironment-initiated mechanism leading to EMT and nominates several potential drug targets whose antagonism may promote PDAC chemoresponse. Citation Format: Brooke A. Brown, Paul J. Myers, Sara J. Adair, Jason R. Pitarresi, Shiv Sah Teli, Peppi Karppinen, Ben Z. Stanger, Todd W. Bauer, Matthew J. Lazzara. Hypoxia promotes a durable epithelial-mesenchymal transition in pancreas cancer through a histone methylation-MAPK signaling axis [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr C054.
- Published
- 2022
15. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer
- Author
-
Harun Ozturk, Harun Cingoz, Turan Tufan, Jiekun Yang, Sara J. Adair, Krishna Seshu Tummala, Cem Kuscu, Meric Kinali, Gamze Comertpay, Sarbajeet Nagdas, Bernadette J. Goudreau, Husnu Umit Luleyap, Yagmur Bingul, Timothy B. Ware, William L. Hwang, Ku-lung Hsu, David F. Kashatus, David T. Ting, Navdeep S. Chandel, Nabeel Bardeesy, Todd W. Bauer, and Mazhar Adli
- Subjects
LIM-Homeodomain Proteins ,Nerve Tissue Proteins ,Cell Biology ,General Biochemistry, Genetics and Molecular Biology ,Epigenesis, Genetic ,Pancreatic Neoplasms ,Cell Line, Tumor ,Tumor Microenvironment ,Humans ,Genes, Tumor Suppressor ,Molecular Biology ,Developmental Biology ,Carcinoma, Pancreatic Ductal ,Transcription Factors - Abstract
Pancreatic ductal adenocarcinoma (PDA) cells reprogram their transcriptional and metabolic programs to survive the nutrient-poor tumor microenvironment. Through in vivo CRISPR screening, we discovered islet-2 (ISL2) as a candidate tumor suppressor that modulates aggressive PDA growth. Notably, ISL2, a nuclear and chromatin-associated transcription factor, is epigenetically silenced in PDA tumors and high promoter DNA methylation or its reduced expression correlates with poor patient survival. The exogenous ISL2 expression or CRISPR-mediated upregulation of the endogenous loci reduces cell proliferation. Mechanistically, ISL2 regulates the expression of metabolic genes, and its depletion increases oxidative phosphorylation (OXPHOS). As such, ISL2-depleted human PDA cells are sensitive to the inhibitors of mitochondrial complex I in vitro and in vivo. Spatial transcriptomic analysis shows heterogeneous intratumoral ISL2 expression, which correlates with the expression of critical metabolic genes. These findings nominate ISL2 as a putative tumor suppressor whose inactivation leads to increased mitochondrial metabolism that may be exploitable therapeutically.
- Published
- 2021
16. Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth
- Author
-
Sara J. Adair, Edward B. Stelow, Sarbajeet Nagdas, Hiromi Sesaki, Todd W. Bauer, Alex D. Michaels, Syed Saad Hussain, Aldo Nascimento, David F. Kashatus, Sarah R. Pollock, Jennifer A. Kashatus, and Riley E. Trainor
- Subjects
0301 basic medicine ,Dynamins ,endocrine system ,Apoptosis ,Mitochondrion ,medicine.disease_cause ,Mitochondrial Dynamics ,General Biochemistry, Genetics and Molecular Biology ,Article ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Pancreatic tumor ,Pancreatic cancer ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Glycolysis ,Phosphorylation ,lcsh:QH301-705.5 ,Cell Proliferation ,Mice, Knockout ,Chemistry ,medicine.disease ,Xenograft Model Antitumor Assays ,Cell biology ,Mitochondria ,Gene Expression Regulation, Neoplastic ,Pancreatic Neoplasms ,030104 developmental biology ,lcsh:Biology (General) ,Mitochondrial fission ,KRAS ,Flux (metabolism) ,030217 neurology & neurosurgery ,Homeostasis - Abstract
SUMMARY Mitochondria undergo fission and fusion to maintain homeostasis, and tumors exhibit the dysregulation of mitochondrial dynamics. We recently demonstrated that ectopic HRasG12V promotes mitochondrial fragmentation and tumor growth through Erk phosphorylation of the mitochondrial fission GTPase Dynamin-related protein 1 (Drp1). However, the role of Drp1 in the setting of endogenous oncogenic KRas remains unknown. Here, we show that Drp1 is required for KRas-driven anchorage-independent growth in fibroblasts and patient-derived pancreatic cancer cell lines, and it promotes glycolytic flux, in part through the regulation of hexokinase 2 (HK2). Furthermore, Drp1 deletion imparts a significant survival advantage in a model of KRas-driven pancreatic cancer, and tumors exhibit a strong selective pressure against complete Drp1 deletion. Rare tumors that arise in the absence of Drp1 have restored glycolysis but exhibit defective mitochondrial metabolism. This work demonstrates that Drp1 plays dual roles in KRas-driven tumor growth: supporting both glycolysis and mitochondrial function through independent mechanisms., In Brief Nagdas et al. find that the mitochondrial fission GTPase Drp1 is required for KRas-driven transformation and pancreatic tumor growth. The inhibition of Drp1 in cells expressing oncogenic KRas leads to impaired glycolytic flux and the eventual loss of mitochondrial metabolic function., Graphical Abstract
- Published
- 2019
17. ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancer
- Author
-
Todd W. Bauer, Turan Tufan, Mazhar Adli, Ku-Lung Hsu, Nabeel Bardeesy, Sarbajeet Nagdas, Husnu Umit Luleyap, Sara J. Adair, Krishna S. Tummala, Dave F. Kashatus, Cem Kuscu, Bernadette J. Goudreau, Jiekun Yang, Gamze Cömertpay, and Harun Cingoz
- Subjects
Biology ,medicine.disease ,medicine.disease_cause ,law.invention ,Downregulation and upregulation ,law ,Pancreatic cancer ,DNA methylation ,Gene expression ,medicine ,Cancer research ,Suppressor ,KRAS ,Epigenetics ,Transcription factor - Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Uncovering mechanisms responsible for the heterogeneous clinical features of this disease is an essential step toward developing improved and more specific therapeutic approaches. Here, we sought to identify transcriptional regulators of aggressive PDAC growth through in vivo CRISPR screening of epigenetic and transcription factors in an orthotopic model. We identified the ISL LIM homeobox 2 (ISL2) gene as a tumor suppressor whose depletion enhances the proliferation of human PDAC cells in vitro and in vivo and cooperates with activated KRAS to initiate PDAC in a murine model. Conversely, the upregulation of ISL2 expression through CRISPR-mediated locus-specific epigenetic editing results in reduced cell proliferation. Importantly, ISL2 is epigenetically silenced through DNA methylation in ~60% of PDAC tumors, which correlates with poor patient outcome. Functional studies showed that ISL2 loss rewires metabolic gene expression, and consequently potentiates oxidative phosphorylation while reducing glycolysis. This metabolic shift creates selective vulnerability to small molecule inhibitors of mitochondrial respiration and fatty acid oxidation. Collectively, these findings reveal ISL2 as a novel tumor suppressor whose inactivation drives metabolic reprogramming in an aggressive PDAC subset and point to potential therapeutic vulnerabilities in these tumors.
- Published
- 2020
18. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
- Author
-
Matthew G. Mullen, Alex D. Michaels, Natasha Lopes Fischer, Mazhar Adli, P. Todd Stukenberg, Sara J. Adair, Karol Szlachta, Todd W. Bauer, Limin Liu, Stephen Shang, Turan Tufan, Edward B. Stelow, Prasad Trivedi, J. Thomas Parsons, Cem Kuscu, and Jiekun Yang
- Subjects
0301 basic medicine ,Drug ,media_common.quotation_subject ,Science ,General Physics and Astronomy ,Mice, Nude ,Antineoplastic Agents ,Biology ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,Article ,03 medical and health sciences ,Gene Knockout Techniques ,Drug Delivery Systems ,In vivo ,Pancreatic cancer ,Cell Line, Tumor ,medicine ,CRISPR ,Animals ,Combinatorial Chemistry Techniques ,Humans ,Clustered Regularly Interspaced Short Palindromic Repeats ,Genetic Testing ,lcsh:Science ,Genetic testing ,media_common ,Mitogen-Activated Protein Kinase Kinases ,Multidisciplinary ,medicine.diagnostic_test ,Cell Death ,Cancer ,Reproducibility of Results ,Drug Synergism ,General Chemistry ,Cell Cycle Checkpoints ,medicine.disease ,3. Good health ,Pancreatic Neoplasms ,030104 developmental biology ,Cancer cell ,Cancer research ,lcsh:Q - Abstract
Predicting the response and identifying additional targets that will improve the efficacy of chemotherapy is a major goal in cancer research. Through large-scale in vivo and in vitro CRISPR knockout screens in pancreatic ductal adenocarcinoma cells, we identified genes whose genetic deletion or pharmacologic inhibition synergistically increase the cytotoxicity of MEK signaling inhibitors. Furthermore, we show that CRISPR viability scores combined with basal gene expression levels could model global cellular responses to the drug treatment. We develop drug response evaluation by in vivo CRISPR screening (DREBIC) method and validated its efficacy using large-scale experimental data from independent experiments. Comparative analyses demonstrate that DREBIC predicts drug response in cancer cells from a wide range of tissues with high accuracy and identifies therapeutic vulnerabilities of cancer-causing mutations to MEK inhibitors in various cancer types., Predicting the response to chemotherapy is a major goal of cancer research. Here the authors use CRISPR knockout screens in pancreatic ductal adenocarcinoma cells to identify deletions synergistic with MEK inhibitors.
- Published
- 2018
19. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
- Author
-
Sara J. Adair, Alex D. Michaels, Craig L. Slingluff, Matthew G. Mullen, Timothy E. Newhook, Sarbajeet Nagdas, J. Thomas Parsons, Kodi S. Ravichandran, Timothy N. J. Bullock, Todd W. Bauer, Sho Morioka, Bernadette J. Goudreau, and Jesse B. Persily
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_treatment ,CD47 Antigen ,Article ,Immunomodulation ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Mice, Inbred NOD ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Macrophage ,Neoplasm Metastasis ,Neoplasm Staging ,Tumor microenvironment ,biology ,business.industry ,Macrophages ,CD47 ,Cancer ,Immunotherapy ,medicine.disease ,Immunohistochemistry ,Xenograft Model Antitumor Assays ,Tumor Burden ,Pancreatic Neoplasms ,Disease Models, Animal ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Disease Progression ,Cancer research ,biology.protein ,Antibody ,business ,Adjuvant - Abstract
Purpose: Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only 2 years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases to identify adjuvant treatment strategies that could prolong survival. Experimental Design: A murine splenic injection model of hepatic micrometastatic PDAC was used with five patient-derived PDAC tumors. The impact of liver macrophages on tumor growth was assessed by (i) depleting mouse macrophages in nude mice with liposomal clodronate injection, and (ii) injecting tumor cells into nude versus NOD-scid-gamma mice. Immunohistochemistry and flow cytometry were used to measure CD47 (“don't eat me signal”) expression on tumor cells and characterize macrophages in the tumor microenvironment. In vitro engulfment assays and mouse experiments were performed with CD47-blocking antibodies to assess macrophage engulfment of tumor cells, progression of micrometastases in the liver and mouse survival. Results: In vivo clodronate depletion experiments and NOD-scid-gamma mouse experiments demonstrated that liver macrophages suppress the progression of PDAC micrometastases. Five patient-derived PDAC cell lines expressed variable levels of CD47. In in vitro engulfment assays, CD47-blocking antibodies increased the efficiency of PDAC cell clearance by macrophages in a manner which correlated with CD47 receptor surface density. Treatment of mice with CD47-blocking antibodies resulted in increased time-to-progression of metastatic tumors and prolonged survival. Conclusions: These findings suggest that following surgical resection of PDAC, adjuvant immunotherapy with anti-CD47 antibody could lead to substantially improved outcomes for patients. Clin Cancer Res; 24(6); 1415–25. ©2017 AACR.
- Published
- 2018
20. Apoptotic Bodies in the Pancreatic Tumor Cell Culture Media Enable Label‐Free Drug Sensitivity Assessment by Impedance Cytometry
- Author
-
Sara J. Adair, John H. Moore, Carlos Honrado, Armita Salahi, Todd W. Bauer, and Nathan S. Swami
- Subjects
Cell ,Cell Culture Techniques ,Biomedical Engineering ,Article ,General Biochemistry, Genetics and Molecular Biology ,Flow cytometry ,Biomaterials ,Extracellular Vesicles ,Pancreatic tumor ,Cell Line, Tumor ,Electric Impedance ,Tumor Microenvironment ,medicine ,Humans ,Distribution (pharmacology) ,medicine.diagnostic_test ,Chemistry ,medicine.disease ,In vitro ,Microvesicles ,Pancreatic Neoplasms ,medicine.anatomical_structure ,Pharmaceutical Preparations ,Apoptosis ,Cancer research ,Cytometry - Abstract
The ability to rapidly and sensitively predict drug response and toxicity using in vitro models of patient-derived tumors is essential for assessing chemotherapy efficacy. Currently, drug sensitivity assessment for solid tumors relies on imaging adherent cells or by flow cytometry of cells lifted from drug-treated cultures after fluorescent staining for apoptotic markers. Subcellular apoptotic bodies (ABs), including microvesicles that are secreted into the culture media under drug treatment can potentially serve as markers for drug sensitivity, without the need to lift cells under culture. However, their stratification to quantify cell disassembly is challenging due to their compositional diversity, with tailored labeling strategies currently needed for the recognition and cytometry of each AB type. It is shown that the high frequency impedance phase versus size distribution of ABs determined by high-throughput single-particle impedance cytometry of supernatants in the media of gemcitabine-treated pancreatic tumor cultures exhibits phenotypic resemblance to lifted apoptotic cells and enables shape-based stratification within distinct size ranges, which is not possible by flow cytometry. It is envisioned that this tool can be applied in conjunction with the appropriate pancreatic tumor microenvironment model to assess drug sensitivity and toxicity of patient-derived tumors, without the need to lift cells from cultures.
- Published
- 2021
21. Abstract PO-007: PRMT5 inhibition sensitizes pancreatic cancer to gemcitabine in orthotopic and metastatic murine models
- Author
-
Sarbajeet Nagdas, William J. Kane, Denis Liu, Sara J. Adair, Mazhar Adli, Todd W. Bauer, and Xiaolong Wei
- Subjects
Cancer Research ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Protein arginine methyltransferase 5 ,Splenectomy ,Cancer ,Magnetic resonance imaging ,medicine.disease ,Gemcitabine ,Oncology ,In vivo ,Pancreatic cancer ,medicine ,Cancer research ,Bioluminescence imaging ,business ,medicine.drug - Abstract
Purpose: The purpose of this study was to investigate protein arginine methyltransferase 5 (PRMT5) as a therapeutic target in combination with gemcitabine for pancreatic cancer in preclinical models. Procedures: In an orthotopic xenograft model, PRMT5 wild-type (WT) or knockout (KO) mPanc96 cells were injected into the pancreata of athymic nude mice. Mice were randomized to control or gemcitabine (100 mg/kg) arms. Tumor volume was measured with magnetic resonance imaging (MRI) at 21, 28, and 35 days post-injection. In a liver metastasis model, PRMT5 WT or KO mPanc96 cells were injected into the spleens of athymic nude mice followed by splenectomy after 10 minutes. Mice were randomized to control or gemcitabine (100 mg/kg) arms. Metastatic tumor burden within the liver was measured with in vivo bioluminescence imaging twice weekly for 19 days post-injection. Relative bioluminescence was calculated relative to post-injection day 2. Results: In the orthotopic model, untreated PRMT5 KO tumors exhibited a 46% reduction in tumor volume compared to untreated PRMT5 WT tumors (959 mm−3 vs. 1766 mm−3, p=0.009). Furthermore, gemcitabine-treated PRMT5 KO tumors exhibited a 30% reduction in tumor volume compared to gemcitabine-treated PRMT5 WT tumors (405 mm−3 vs. 579 mm−3, p=0.046). Compared to untreated PRMT5 WT tumors, gemcitabine-treated PRMT5 KO tumors exhibited a 77% reduction in tumor volume (405 mm−3 vs. 1766 mm−3, p= Citation Format: William J. Kane, Sara J. Adair, Sarbajeet Nagdas, Denis Liu, Xiaolong Wei, Mazhar Adli, Todd W. Bauer. PRMT5 inhibition sensitizes pancreatic cancer to gemcitabine in orthotopic and metastatic murine models [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr PO-007.
- Published
- 2020
22. Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer
- Author
-
Sara J. Adair, Todd W. Bauer, Arabinda Mandal, Kiley A. Knapp, Anne M. Mills, Craig L. Slingluff, John C. Herr, J. Thomas Parsons, Timothy N. J. Bullock, Walter C. Olson, and Eusebio S. Pires
- Subjects
0301 basic medicine ,Cellular immunity ,Antibody-drug conjugate ,Antibody-Drug Conjugate Therapy ,medicine.drug_class ,Cell ,Monoclonal antibody ,antibody-drug conjugate ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Immunotoxin ,Pancreatic cancer ,Medicine ,business.industry ,ASTL/SAS1B/ovastacin ,surface cancer-oocyte antigen ,medicine.disease ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,pancreatic cancer biomarker ,Cancer research ,targeted immunotherapy ,business ,Research Paper - Abstract
Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide therapeutic approaches if antigens specific for pancreatic cancer cells can be identified. Here we characterize SAS1B (ovastacin, ASTL, astacin-like), a cancer-oocyte antigen, as an attractive immunotoxin target expressed at the surface of human pancreatic cancer cells, with limited expression among normal tissues. Immunohistochemistry shows that most pancreatic cancers are SAS1Bpos (68%), while normal pancreatic ductal epithelium is SAS1Bneg. Pancreatic cancer cell lines developed from patient-derived xenograft models display SAS1B cell surface localization, in addition to cytoplasmic expression, suggesting utility for SAS1B in multiple immunotherapeutic approaches. When pancreatic cancer cells were treated with an anti-SAS1B antibody-drug conjugate, significant cell death was observed at 0.01-0.1 μg/mL, while SAS1Bneg human keratinocytes were resistant. Cytotoxicity was correlated with SAS1B cell surface expression; substantial killing was observed for tumors with low steady state SAS1B expression, suggesting a substantial proportion of SAS1Bpos tumors can be targeted in this manner. These results demonstrate SAS1B is a surface target in pancreatic cancer cells capable of binding monoclonal antibodies, internalization, and delivering cytotoxic drug payloads, supporting further development of SAS1B as a novel target for pancreatic cancer.
- Published
- 2017
23. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis
- Author
-
J. Thomas Parsons, Osama E. Rahma, Alison J. Kim, James M. Lindberg, Timothy E. Newhook, Sara J. Adair, Edward B. Stelow, and Todd W. Bauer
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,endocrine system diseases ,Pyridones ,medicine.medical_treatment ,Pyrimidinones ,medicine.disease_cause ,Article ,Metastasis ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Pancreatic cancer ,Internal medicine ,medicine ,Carcinoma ,Tumor Cells, Cultured ,Animals ,Humans ,Protein Kinase Inhibitors ,Trametinib ,business.industry ,MEK inhibitor ,Liver Neoplasms ,medicine.disease ,Xenograft Model Antitumor Assays ,Gemcitabine ,Pancreatic Neoplasms ,030104 developmental biology ,030220 oncology & carcinogenesis ,Surgery ,KRAS ,business ,Adjuvant ,medicine.drug ,Carcinoma, Pancreatic Ductal - Abstract
Most patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult liver metastases in a preclinical model. Liver metastases harvested from two patients with PDAC (Tumors 608, 366) were implanted orthotopically in mice. Tumor cell lines were derived and transduced with lentiviruses encoding luciferase and injected into spleens of mice generating microscopic liver metastases. Growth kinetics of liver metastases were measured with bioluminescent imaging and time-to-progression (TTP), progression-free survival (PFS), and overall survival (OS) were determined. Trametinib (0.3 mg/kg BID) significantly prolonged OS versus control (Tumor 608: 114 vs. 43 days, p
- Published
- 2015
24. Abstract A47: A patient-derived xenograft model of pancreatic cancer in mice to develop novel adjuvant therapies
- Author
-
J. Thomas Parsons, Matthew G. Mullen, Edward B. Stelow, Timothy E. Newhook, Todd W. Bauer, Sara J. Adair, Alex D. Michaels, Jason A. Papin, James M. Lindberg, and Edik M. Blais
- Subjects
Trametinib ,Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,MEK inhibitor ,Cancer ,medicine.disease ,Gemcitabine ,Metastasis ,Oncology ,Pancreatic cancer ,Cancer research ,Adjuvant therapy ,medicine ,Bioluminescence imaging ,business ,medicine.drug - Abstract
Background: Eighty percent of patients with pancreatic ductal adenocarcinoma (PDAC) die from their disease within five years of surgical resection, likely due to presence of occult metastases at diagnosis. We have developed a patient-derived xenograft (PDX) model in mice to investigate the behavior of occult metastatic cells in the liver microenvironment and derive novel adjuvant therapies. Methods: Five PDAC tumors (215, 366, 608, 654 and 738) were resected from patients and implanted orthotopically in mice. Tumors were harvested, cell lines generated and transduced with luciferase, then injected into spleens of mice to generate microscopic liver metastases, then primary tumors removed via splenectomy. Bioluminescence imaging of mice and histologic analysis and flow cytometry of livers were utilized to characterize each tumor's distinct pattern of cell clearance and outgrowth kinetics. Affymetrix gene expression of tumors was performed. Mice were treated with adjuvant therapy following resection of primary tumors in the spleen and time-to-progression (TTP) and overall survival (OS) were measured. Results: Each PDX cell line demonstrated unique and reproducible clearance in the liver and outgrowth kinetics as measured by bioluminescence imaging. Distinct differences in gene expression were identified in tumors exhibiting rapid vs. delayed outgrowth. The MEK inhibitor trametinib (0.3 mg/kg oral daily) prolonged TTP and OS vs. control (OS - Tumor 608: 114 vs. 43 days, p Conclusions: This PDX PDAC model of occult metastasis allows characterization of hepatic clearance of tumor cells and outgrowth kinetics. Metastatic outgrowth appears to be dependent upon distinguishable tumor cell-specific factors. Trametinib effectively inhibits KRAS-MEK-ERK signaling, delays outgrowth of occult metastases and prolongs survival of mice. Utilization of this model will help further define the complex interaction of PDAC cells and the metastatic microenvironment of the liver. Citation Format: Matthew G. Mullen, Timothy E. Newhook, James M. Lindberg, Sara J. Adair, Edik M. Blais, Alex D. Michaels, Edward B. Stelow, Jason A. Papin, J. Thomas Parsons, Todd W. Bauer. A patient-derived xenograft model of pancreatic cancer in mice to develop novel adjuvant therapies. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr A47.
- Published
- 2016
25. Abstract B21: In a patient-derived xenograft model of occult hepatic metastasis from pancreatic cancer the MEK inhibitor trametinib delays tumor outgrowth and prolongs survival
- Author
-
James M. Lindberg, Timothy E. Newhook, Sara J. Adair, Todd W. Bauer, and J. Thomas Parsons
- Subjects
Trametinib ,Cancer Research ,ved/biology ,business.industry ,medicine.medical_treatment ,MEK inhibitor ,ved/biology.organism_classification_rank.species ,Splenectomy ,medicine.disease ,Oncology ,Apoptosis ,Tumor progression ,Pancreatic cancer ,Adjuvant therapy ,medicine ,Cancer research ,Model organism ,business ,Molecular Biology - Abstract
Background: Survival for patients with pancreatic ductal adenocarcinoma (PDAC) remains dismal and the majority of patients succumb to metastatic disease. Even for those with localized PDAC, most will die from metastatic disease despite margin-negative resection and adjuvant therapy. Therefore, these patients must harbor occult metastatic PDAC at presentation. There is a compelling need for the development of preclinical models that efficiently recapitulate occult metastatic liver PDAC to identify molecular and cellular pathways that drive metastatic cellular survival and growth. Towards this aim, we have developed a PDAC model of occult liver metastases using patient-derived xenografts (PDXs) to study the growth of PDAC within the metastatic environment and evaluated the effect of MEK inhibitor therapy on tumor progression. Methods and Results: Extensively characterized patient-derived KRAS-mutant (Tumors 608, 366, and 654) and wild-type (Tumors 738 and 215) PDAC cells were transduced with luciferase and injected into the spleens of athymic, nude mice, allowed to circulate for 10 minutes, after which a splenectomy was performed. To evaluate metastatic cell growth kinetics in the liver, tumor burden was monitored by sequential bioluminescent imaging. All mice exhibited defined phases of survival/dormancy and the proliferative outgrowth; however, differential kinetics were observed for each tumor cell line. To evaluate the effect of MEK inhibition of occult metastatic PDAC cells in the liver, Tumor 608 cells were injected and mice either received the MEK inhibitor trametinib (0.3 mg/kg, daily) or vehicle control beginning 48 hour post-injection. Trametinib significantly reduced metastatic tumor burden, delayed time to proliferative outgrowth, and greatly prolonged survival as compared to control (med. survival: 114 vs. 43 days, p Conclusions: In a model of occult liver metastatic PDAC, patient-derived tumors exhibit different growth kinetics in the liver environment. Furthermore, MEK inhibition with trametinib decreased metastatic cellular proliferation, increased apoptosis, prolonged metastatic tumor outgrowth, and significantly increased survival of mice harboring occult hepatic metastases from PDAC. This efficacy of single agent trametinib is unique to occult metastatic disease and is not seen in orthotopic models of advanced, established pancreatic tumors. This finding illustrates the importance of using specific preclinical models that best recapitulate the clinical aspects of patients who will be evaluated in future clinical trials. Further investigation into the cellular and molecular factors promoting PDAC cell survival within the hepatic microenvironment utilizing this model will lead to development of rational therapeutic strategies for patients with occult metastatic disease. Citation Format: Timothy Newhook, James Lindberg, Sara Adair, J. Thomas Parsons, Todd W. Bauer. In a patient-derived xenograft model of occult hepatic metastasis from pancreatic cancer the MEK inhibitor trametinib delays tumor outgrowth and prolongs survival. [abstract]. In: Proceedings of the AACR Special Conference: The Translational Impact of Model Organisms in Cancer; Nov 5-8, 2013; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(11 Suppl):Abstract nr B21.
- Published
- 2014
26. Abstract 808: Combination therapy with a MEK inhibitor plus T-type calcium channel inhibitor is highly effective in patient-derived pancreatic ductal adenocarcinomas
- Author
-
J. Thomas Parsons, Timothy E. Newhook, Jason A. Papin, James M. Lindberg, Sara J. Adair, Lloyd S. Gray, Edik M. Blais, and Todd W. Bauer
- Subjects
Trametinib ,Cancer Research ,Mibefradil ,endocrine system diseases ,Combination therapy ,business.industry ,MEK inhibitor ,T-type calcium channel ,Cancer ,Pharmacology ,medicine.disease ,medicine.disease_cause ,digestive system diseases ,chemistry.chemical_compound ,Oncology ,chemistry ,medicine ,Cancer research ,KRAS ,Growth inhibition ,business ,medicine.drug - Abstract
Introduction: Survival for patients with pancreatic ductal adenocarcinoma (PDAC) remains dismal and novel therapeutic strategies are needed. Mutations in the KRAS oncogene are important drivers of PDAC progression; however, monotherapies targeting the RAS pathway have shown only modest efficacy. The RAS pathway is an activator of calcium (Ca2+) signaling, which has been implicated in PDAC progression. We hypothesized that MEK inhibition combined with the T-type calcium channel inhibitor mibefradil would result in enhanced growth inhibition of PDAC tumors. Methods and Results: Gene expression profiling of patient-derived PDAC tumors (relative to normal pancreas) and tumors chronically treated with the MEK inhibitor trametinib in vivo revealed an upregulation of Ca2+-signaling related genes including members of the calpain pathway and the calmodulin pathway, both implicated in PDAC progression. To assess the in vivo efficacy of combined T-type calcium channel inhibition and MEK inhibition, mice were engrafted orthotopically with patient-derived KRAS-mutant (Tumor 366) and KRAS-wild type (Tumor 738) PDAC tumors and treated with control, the MEK inhibitor trametinib, the T-type calcium channel inhibitor mibefradil, or combination. Combination therapy with trametinib plus mibefradil was highly effective with greater inhibition of PDAC growth than either therapy alone in the KRAS-mutant Tumor 366, however mibefradil did not augment the level of growth inhibition achieved by trametinib alone in the KRAS-wild type Tumor 738. To evaluate combination trametinib plus mibefradil therapy in patient-derived PDAC tumors following chronic treatment with trametinib, mice were engrafted orthotopically with patient-derived PDAC tumors, allowed to grow to 300-500mm3, and treated with trametinib for 4-6 weeks. Following initial treatment, tumors were harvested, re-implanted, and again exposed to therapy over 4-6 weeks. The cycles of treatment and reimplantation were continued until tumor growth was not significantly reduced by trametinib treatment. Therapy with trametinib plus mibefradil nearly completely inhibited growth in KRAS-mutant PDAC tumors (Tumors 608 and 366) previously resistant to chronic trametinib therapy. Conclusions: Combination therapy with the MEK inhibitor trametinib plus the T-type calcium channel inhibitor mibefradil results in significant growth inhibition of KRAS-mutant patient-derived PDAC tumors. Moreover, this combination therapy results in near complete growth inhibition of PDAC tumors that have acquired resistance to trametinib. The combination therapy of mibefradil plus trametinib should be further evaluated in clinical trials for patients with PDAC. Citation Format: Timothy Eric Newhook, James M. Lindberg, Sara J. Adair, Edik Blais, Jason Papin, Lloyd Gray, J. Thomas Parsons, Todd W. Bauer. Combination therapy with a MEK inhibitor plus T-type calcium channel inhibitor is highly effective in patient-derived pancreatic ductal adenocarcinomas. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 808. doi:10.1158/1538-7445.AM2014-808
- Published
- 2014
27. Abstract 4040: The MEK inhibitor trametinib delays tumor outgrowth and prolongs survival in a patient-derived mouse model of occult hepatic metastatic pancreatic cancer
- Author
-
Timothy E. Newhook, James M. Lindberg, Todd W. Bauer, J. Thomas Parsons, and Sara J. Adair
- Subjects
Trametinib ,Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,MEK inhibitor ,Splenectomy ,Cancer ,medicine.disease_cause ,medicine.disease ,Oncology ,Tumor progression ,Apoptosis ,medicine ,Cancer research ,Adjuvant therapy ,KRAS ,business - Abstract
Background: Survival for patients with pancreatic ductal adenocarcinoma (PDAC) remains dismal and the majority of patients succumb to metastatic disease. Even for those with localized PDAC, most will die from metastatic disease despite margin-negative resection and adjuvant therapy. Therefore, these patients must harbor occult metastatic PDAC at presentation. We have developed a PDAC model of occult liver metastases using patient-derived xenografts (PDXs) to study the growth of PDAC within the metastatic microenvironment of the liver and evaluated the role of KRAS-MEK-ERK signaling on tumor progression. Methods and Results: Extensively characterized low passage, patient-derived KRAS-mutant (Tumors 608, 366, and 654) and wild-type (Tumors 738 and 215) PDAC cells expressing luciferase were injected into the spleens of athymic, nude mice and allowed to circulate for 10 minutes, after which a splenectomy was performed. To evaluate metastatic cell growth kinetics in the liver, tumor burden was monitored by sequential bioluminescent imaging. Each of the PDX tumors exhibited a characteristic and reproducible time to proliferative outgrowth ranging from 20 days (Tumor 608) to greater than 100 days (Tumor 654). To evaluate the role of KRAS signaling in maintaining dormant cell survival and proliferative outgrowth, tumor 608 cells were injected and mice were treated with the MEK inhibitor trametinib (0.3 mg/kg, daily) or control beginning 48 hours post-injection. Trametinib significantly reduced metastatic tumor burden, delayed time to proliferative outgrowth, and greatly prolonged survival as compared to control (med. survival: 114 vs. 43 days, p Conclusions: Using a model of occult liver metastatic PDAC, patient-derived tumors exhibited characteristic, albeit different growth kinetics in the liver microenvironment. Further, inhibition of KRAS-MEK-ERK signaling with the MEK inhibitor trametinib decreased metastatic cellular proliferation, increased apoptosis, prolonged metastatic tumor outgrowth, and significantly increased survival. Further investigation into factors promoting PDAC cell survival within the hepatic microenvironment will lead to development of rational therapeutic strategies for patients with occult metastatic PDAC. Citation Format: Timothy Eric Newhook, James M. Lindberg, Sara J. Adair, J. Thomas Parsons, Todd W. Bauer. The MEK inhibitor trametinib delays tumor outgrowth and prolongs survival in a patient-derived mouse model of occult hepatic metastatic pancreatic cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4040. doi:10.1158/1538-7445.AM2014-4040
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.